

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1 NAME OF THE MEDICINAL PRODUCT

Nifedilong 30 mg prolonged-release tablets  
Nifedilong 60 mg prolonged-release tablets

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each prolonged-release tablet contains 30 or 60 mg nifedipine, respectively.

For the full list of excipients, see section 6.1.

### 3 PHARMACEUTICAL FORM

Prolonged-release film-coated tablet.

Round biconvex tablets with a pale red colour.

### 4. CLINICAL PARTICULARS

#### 4.1. Therapeutic indications

For the treatment of chronic stable angina and hypertension.

#### 4.2 Posology and method of administration

##### Posology

##### *Adults:*

Dosage must be adjusted according to each patient's needs. Therapy for either hypertension or angina should be initiated with 30 or 60 mg once daily.

*Nifedilong Prolonged Release tablets* should be swallowed whole and should not be bitten or divided. In general, titration should proceed over at 7-14 day period so that the physician can fully assess the response to each dose level and monitor blood pressure before proceeding to higher doses. Since steady-state plasma levels are achieved on the second day of dosing, if symptoms so warrant, titration may proceed more rapidly provided the patient is assessed frequently. Titration to doses above 120 mg are not recommended.

### *A Switch over from Nifedipine capsules to Nifedilong*

Angina patients controlled on Nifedipine capsules alone or in combination with other antianginal medications may be safely switched to Nifedilong Prolonged Release tablets at the nearest, equivalent total daily dose (e.g. 1 Nifedipine capsule of 10 mg t.i.d. up to q.i.d. may be changed to 30 mg once daily of Nifedilong Prolonged Release tablet). Subsequent titration to higher doses may be necessary and should be initiated as clinically warranted. Experience with doses greater than 90 mg in patients with angina is limited. Therefore, doses greater than 90 mg should be used with caution and only when clinically warranted.

No "rebound effect" has been observed upon discontinuation of Nifedilong Prolonged Release tablets. However, if discontinuation of nifedipine is necessary the dosage should be decreased gradually with close physician supervision.

### *Switch over from Nifedipine tablets to Nifedilong*

Patients controlled on Nifedipine tablets may be safely switched to Nifedilong Prolonged Release tablets at the nearest equivalent total daily dose (e.g., 1 Nifedipine tablet of 10 mg t.i.d. or 20 mg b.i.d. may be changed to 30 mg once daily of Nifedilong Prolonged Release tablet).

### *Co-administration with other Anti-anginal drugs*

Sublingual nitroglycerin may be taken as required for the control of acute manifestations of angina, particularly during nifedipine titration. See Special Warnings and special Precautions, Interactions with other medicinal products, for information on co-administration of nifedipine with beta blockers or long acting nitrates.

As a rule, *Nifedilong Prolonged Release tablets* should be swallowed whole with a little water independently of mealtimes. Under no circumstances should they be chewed or broken up.

The medication is formulated in such way that it releases the active substance in the intestine with a practically constant rate over a 16 to 18 hour time period.

Co-administration with CYP 3A4 inhibitors or CYP 3A4 inducers may result in the recommendation to adapt the nifedipine dose or not to use nifedipine at all (see section 4.5).

### *Duration of treatment*

The attending doctor will determine the duration of use.

### *Additional information on special populations*

### *Paediatric population*

The safety and efficacy of Nifedilong in children below 18 years has not been established. Currently available data for the use of nifedipine in hypertension are described in section 5.1

### *Elderly*

Based on pharmacokinetic data for Nifedilong no dose adaptation in elderly people above 65 years is necessary.

### *Renal impairment*

Based on pharmacokinetic data, no dosage adjustment is required in patients with renal impairment (see section 5.2).

### Method of administration

Oral use.

The tablets should be swallowed whole with a glass of water, either with or without food. The tablets should be taken at approximately 24-hour intervals, i.e., at the same time each day, preferably during the morning. Nifedilong tablets must be swallowed whole; under no circumstances should they be bitten, chewed or broken up.

Nifedilong should not be taken with grapefruit juice (see section 4.5).

## **4.3 Contraindications**

Nifedilong should not be administered to patients with known hypersensitivity to the active substance, or to other dihydropyridines because of the theoretical risk of cross-reactivity, or to any of the excipients listed in sections 4.4 and 6.1.

Nifedilong should not be used in cases of cardiogenic shock, clinically significant aortic stenosis, unstable angina, or during or within one month of a myocardial infarction.

Nifedilong should not be used for the treatment of acute attacks of angina. The safety of Nifedilong in malignant hypertension has not been established.

Nifedilong should not be used for secondary prevention of myocardial infarction. Owing to the duration of action of the formulation, Nifedilong should not be administered to patients with hepatic impairment.

Nifedilong should not be administered to patients with a history of gastrointestinal obstruction, oesophageal obstruction, or any degree of decreased lumen diameter of the gastro-intestinal tract.

Nifedilong must not be used in patients with a Kock pouch (ileostomy after proctocolectomy).

Nifedilong is contra-indicated in patients with inflammatory bowel disease or

Crohn's disease.

Nifedilong should not be administered concomitantly with rifampicin since effective plasma levels of nifedipine may not be achieved owing to enzyme induction (see section 4.5).

#### **4.4 Special warnings and precautions for use**

Nifedilong tablets must be swallowed whole; under no circumstances should they be bitten, chewed or broken up.

Caution should be exercised in patients with hypotension as there is a risk of further reduction in blood pressure and care must be exercised in patients with very low blood pressure (severe hypotension with systolic blood pressure less than 90 mm Hg).

Nifedilong should not be used during pregnancy unless the clinical condition of the woman requires treatment with nifedipine. Nifedilong should be reserved for women with severe hypertension who are unresponsive to standard therapy (see section 4.6).

Careful monitoring of blood pressure must be exercised when administering nifedipine with I.V. magnesium sulfate, owing to the possibility of an excessive fall in blood pressure, which could harm both mother and foetus. For further information regarding use in pregnancy, refer to section 4.6.

Nifedilong is not recommended for use during breast-feeding because nifedipine has been reported to be excreted in human milk and the effects of nifedipine exposure to the infant are not known (see section 4.6).

In patients with impaired liver function careful monitoring and, in severe cases, a dose reduction may be necessary.

Nifedilong may be used in combination with beta-blocking drugs and other antihypertensive agents but the possibility of an additive effect resulting in postural hypotension should be borne in mind. Nifedilong will not prevent possible rebound effects after cessation of other antihypertensive therapy.

Nifedilong should be used with caution in patients whose cardiac reserve is poor. Deterioration of heart failure has occasionally been observed with nifedipine.

Diabetic patients taking Nifedilong may require adjustment of their control. In dialysis patients with malignant hypertension and hypovolaemia, a marked decrease in blood pressure can occur.

Nifedipine is metabolised via the cytochrome P450 3A4 system. Drugs that are known to either inhibit or to induce this enzyme system may therefore alter the

first pass or the clearance of nifedipine (see section 4.5).

Drugs, which are known inhibitors of the cytochrome P450 3A4 system, and which may therefore lead to increased plasma concentrations of nifedipine include, for example:

- macrolide antibiotics (e.g., erythromycin)
- anti-HIV protease inhibitors (e.g., ritonavir)
- azole antimycotics (e.g., ketoconazole)
- the antidepressants, nefazodone and fluoxetine
- quinupristin/dalfopristin
- valproic acid
- cimetidine

Upon co-administration with these drugs, the blood pressure should be monitored and, if necessary, a reduction of the nifedipine dose should be considered.

As the outer membrane of the Nifedilong tablet is not digested, what appears to be the complete tablet may be seen in the toilet or associated with the patient's stools. Also, as a result of this, care should be exercised when administering Nifedilong to patients, as obstructive symptoms may occur. Bezoars can occur in very rare cases and may require surgical intervention.

In single cases, obstructive symptoms have been described without known history of gastrointestinal disorders.

A false positive effect may be experienced when performing a barium contrast x-ray. For use in special populations see section 4.2.

#### **4.5 Interactions with other medicinal products and other forms of interaction**

##### Drugs that affect nifedipine

Nifedipine is metabolised via the cytochrome P450 3A4 system, located both in the intestinal mucosa and in the liver. Drugs that are known to either inhibit or to induce this enzyme system may therefore alter the first pass (after oral administration) or the clearance of nifedipine.

The extent as well as the duration of interactions should be taken into account when administering nifedipine together with the following drugs:

*Rifampicin:* Rifampicin strongly induces the cytochrome P450 3A4 system. Upon co-administration with rifampicin, the bioavailability of nifedipine is distinctly reduced and thus its efficacy weakened. The use of nifedipine in combination with rifampicin is therefore contraindicated (see Section 4.3).

Upon co-administration of known inhibitors of the cytochrome P450 3A4 system, the blood pressure should be monitored and, if necessary, a reduction in the nifedipine dose considered (see Sections 4.2 and 4.4). In the majority of these cases, no formal studies to assess the potential for a drug interaction between nifedipine and the drug(s) listed have been undertaken, thus far.

#### Drugs increasing nifedipine exposure:

- *macrolide antibiotics (e.g. erythromycin)*
- *anti-HIV protease inhibitors (e.g. ritonavir)*
- *azole anti-mycotics (e.g., ketoconazole)*
- *fluoxetine*
- *nefazodone*
- *quinupristin/dalfopristin*
- *cisapride*
- *valproic acid*
- *cimetidine*
- *diltiazem*

Upon co-administration of inducers of the cytochrome P450 3A4 system, the clinical response to nifedipine should be monitored and, if necessary, an increase in the nifedipine dose considered. If the dose of nifedipine is increased during co-administration of both drugs, a reduction of the nifedipine dose should be considered when the treatment is discontinued.

#### Drugs decreasing nifedipine exposure:

- *rifampicin (see above)*
- *phenytoin*
- *carbamazepine*
- *phenobarbital*

#### Effects of nifedipine on other drugs

Nifedipine may increase the blood pressure lowering effect of concomitant applied antihypertensives.

When nifedipine is administered simultaneously with  $\beta$ -receptor blockers the patient should be carefully monitored, since deterioration of heart failure is also known to develop in isolated cases.

*Digoxin:* The simultaneous administration of nifedipine and digoxin may lead to reduced digoxin clearance and, hence, an increase in the plasma digoxin level. The patient should therefore be subjected to precautionary checks for symptoms of digoxin overdose and, if necessary, the glycoside dose should be reduced.

*Quinidine*: Co-administration of nifedipine with quinidine may lower plasma quinidine levels, and after discontinuation of nifedipine, a distinct increase in plasma quinidine levels may be observed in individual cases. Consequently, when nifedipine is either additionally administered or discontinued, monitoring of the quinidine plasma concentration, and if necessary, adjustment of the quinidine dose is recommended. Blood pressure should be carefully monitored and, if necessary, the dose of nifedipine should be decreased.

*Tacrolimus*: Tacrolimus is metabolised via the cytochrome P450 3A4 system. Published data indicate that the dose of tacrolimus administered simultaneously with nifedipine may be reduced in individual cases. Upon co-administration of both drugs, the tacrolimus plasma concentrations should be monitored and, if necessary, a reduction in the tacrolimus dose considered.

#### Drug food interactions

Grapefruit juice inhibits the cytochrome P450 3A4 system. Administration of nifedipine together with grapefruit juice thus results in elevated plasma concentrations and prolonged action of nifedipine due to a decreased first pass metabolism or reduced clearance. As a consequence, the blood pressure lowering effect of nifedipine may be increased. After regular intake of grapefruit juice, this effect may last for at least three days after the last ingestion of grapefruit juice. Ingestion of grapefruit/grapefruit juice is therefore to be avoided while taking nifedipine (see Section 4.2).

#### Other forms of interaction

Nifedipine may increase the spectrophotometric values of urinary vanillylmandelic acid, falsely. However, HPLC measurements are unaffected.

## **4.6 Fertility, pregnancy and lactation**

### **Pregnancy**

Nifedipine should not be used during pregnancy unless the clinical condition of the woman requires treatment with nifedipine (see section 4.4).

In animal studies, nifedipine has been shown to produce embryotoxicity, foetotoxicity and teratogenicity (see section 5.3).

There are no adequate well controlled studies in pregnant women.

From the clinical evidence available a specific prenatal risk has not been identified, although an increase in perinatal asphyxia, caesarean delivery, as well as prematurity and intrauterine growth retardation have been reported. It is unclear whether these

reports are due to the underlying hypertension, its treatment, or to a

specific drug effect.

The available information is inadequate to rule out adverse drug effects on the unborn and newborn child. Therefore, any use in pregnancy requires a very careful individual risk benefit assessment and should only be considered if all other treatment options are either not indicated or have failed to be efficacious.

Acute pulmonary oedema has been observed when calcium channel blockers, among others nifedipine, have been used as a tocolytic agent during pregnancy (see section 4.8), especially in cases of multiple pregnancy (twins or more), with the intravenous route and/or concomitant use of beta-2 agonists.

### **Breast-feeding**

Nifedipine is excreted in the breast milk. The nifedipine concentration in the milk is almost comparable with mother serum concentration. For immediate release formulations, it is proposed to delay breast-feeding or milk expression for 3 to 4 hours after drug administration to decrease the nifedipine exposure to the infant (see section 4.4).

### **Fertility**

In single cases of *in vitro* fertilisation calcium antagonists like nifedipine have been associated with reversible biochemical changes in the spermatozoa's head section that may result in impaired sperm function. In those men who are repeatedly unsuccessful in fathering a child by *in vitro* fertilisation, and where no other explanation can be found, calcium antagonists like nifedipine should be considered as possible causes.

## **4.7 Effects on ability to drive and use machines**

Reactions to the drug, which vary in intensity from individual to individual, may impair the ability to drive or to operate machinery (see Section 4.8). This applies particularly at the start of treatment, on changing the medication and in combination with alcohol.

## **4.8 Undesirable effects**

Adverse drug reactions (ADRs) based on placebo-controlled studies with nifedipine sorted by CIOMS III categories of frequency (clinical trial data base: nifedipine n = 2,661; placebo n = 1,486; status: 22 Feb 2006 and the ACTION study: nifedipine n = 3,825; placebo n = 3,840) are listed below: ADRs listed under "common" were observed with a frequency below 3% with the exception of oedema (9.9%) and headache (3.9%).

The frequencies of ADRs reported with nifedipine-containing products

are summarised in the table below. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Frequencies are defined as common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1,000$  to  $< 1/100$ ) and rare ( $\geq 1/10,000$  to  $< 1/1,000$ ). The ADRs identified only during the ongoing postmarketing surveillance, and for which a frequency could not be estimated, are listed under "Not known".

<b>System Organ Class (MedDRA)</b>	<b>Common</b>	<b>Uncommon</b>	<b>Rare</b>	<b>Not Known</b>
<b>Blood and</b>				Agranulocytosis
<b>Lymphatic System Disorders</b>				Leucopenia
<b>Immune System Disorders</b>		Allergic reaction Allergic oedema/angioedema (incl. larynx oedema <sup>*</sup> )	Pruritus Urticaria Rash	Anaphylactic/anaphylactoid reaction
<b>Psychiatric Disorders</b>		Anxiety reactions Sleep disorders		Depression
<b>Metabolism and Nutrition Disorders</b>				Hyperglycaemia
<b>Nervous System Disorders</b>	Headache	Vertigo Migraine Dizziness Tremor	Par-Dysaesthesia	Hypoaesthesia Somnolence
<b>Eye Disorders</b>		Visual disturbances		Eye pain
<b>Cardiac Disorders</b>		Tachycardia Palpitations		Chest pain (Angina pectoris)
<b>Vascular Disorders</b>	Oedema (incl. peripheral oedema) Vasodilatation	Hypotension Syncope		
<b>Respiratory, Thoracic, and Mediastinal Disorders</b>		Nosebleed Nasal congestion		Dyspnoea Pulmonary oedema <sup>**</sup>

<b>Gastrointestinal Disorders</b>	Constipation	Gastrointestinal and abdominal pain Nausea Dyspepsia Flatulence Dry mouth	Gingival hyperplasia	Bezoar Dysphagia Intestinal obstruction Intestinal ulcer Vomiting Gastroesophageal sphincter insufficiency
<b>Hepatobiliary Disorders</b>		Transient increase in liver enzymes		Jaundice
<b>Skin and Subcutaneous Tissue Disorders</b>		Erythema		Toxic Epidermal Necrolysis Photosensitivity allergic reaction Palpable purpura
<b>Musculoskeletal and Connective Tissue Disorders</b>		Muscle cramps Joint swelling		Arthralgia Myalgia
<b>Renal and Urinary Disorders</b>		Polyuria Dysuria		
<b>Reproductive System and Breast Disorders</b>		Erectile dysfunction		
<b>General Disorders and Administration Site Conditions</b>	Feeling unwell	Unspecific pain Chills		

\* = may result in life-threatening outcome

\*\* cases have been reported when used as tocolytic during pregnancy (see section 4.6)

In dialysis patients with malignant hypertension and hypovolaemia a distinct fall in blood pressure can occur as a result of vasodilation.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form <https://sideeffects.health.gov.il/>

## 4.9 Overdose

### *Symptoms*

The following symptoms are observed in cases of severe nifedipine intoxication: Disturbances of consciousness to the point of coma, a drop in blood pressure, tachycardia, bradycardia, hyperglycaemia, metabolic acidosis, hypoxia, cardiogenic shock with pulmonary oedema.

### *Treatment*

As far as treatment is concerned, elimination of nifedipine and the restoration of stable cardiovascular conditions have priority. Elimination must be as complete as possible, including the small intestine, to prevent the otherwise inevitable subsequent absorption of the active substance.

The benefit of gastric decontamination is uncertain.

1. Consider activated charcoal (50 g for adults, 1 g/kg for children) if the patient presents within 1 hour of ingestion of a potentially toxic amount.

Although it may seem reasonable to assume that late administration of activated charcoal may be beneficial for sustained release (SR, MR) preparations there is no evidence to support this.

2. Alternatively consider gastric lavage in adults within 1 hour of a potentially life-threatening overdose.
3. Consider further doses of activated charcoal every 4 hours if a clinically significant amount of a sustained release preparation has been ingested with a single dose of an osmotic laxative (e.g., sorbitol, lactulose or magnesium sulfate).
4. Asymptomatic patients should be observed for at least 4 hours after ingestion and for 12 hours if a sustained release preparation has been taken.

Haemodialysis serves no purpose as nifedipine is not dialysable, but plasmapheresis is advisable (high plasma protein binding, relatively low volume of distribution).

Hypotension as a result of cardiogenic shock and arterial vasodilatation can be treated with calcium (10-20 ml of a 10 % calcium gluconate solution administered intravenously over 5-10 minutes). If the effects are inadequate, the treatment can be continued, with ECG monitoring. If an insufficient increase in blood pressure is achieved with calcium, vasoconstricting sympathomimetics such as dopamine or noradrenaline should be administered. The dosage of these drugs should be determined

by the patient's response.

Symptomatic bradycardia may be treated with atropine, beta-sympathomimetics or a temporary cardiac pacemaker, as required.

Additional fluids should be administered with caution to avoid cardiac overload.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: selective calcium channel blockers with mainly vascular effect, dihydropyridine derivatives, ATC code: C08CA05

Nifedipine is a calcium antagonist of the 1,4-dihydropyridine type. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell. As a specific and potent calcium antagonist, nifedipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. The main action of nifedipine is to relax arterial smooth muscle, both in the coronary and peripheral circulation.

The Nifedilong tablet is formulated to achieve controlled delivery of nifedipine in a release profile sufficient to enable once-daily administration to be effective in clinical use.

In hypertension, the main action of nifedipine is to cause peripheral vasodilatation and thus reduce peripheral resistance. Nifedipine administered once-daily provides 24-hour control of raised blood pressure. Nifedipine causes reduction in blood pressure such that the percentage lowering is proportional to its initial level. In normotensive individuals, nifedipine has little or no effect on blood pressure.

In angina, Nifedilong reduces peripheral and coronary vascular resistance, leading to an increase in coronary blood flow, cardiac output and stroke volume, whilst decreasing after-load. Additionally, nifedipine dilates submaximally both clear and atherosclerotic coronary arteries, thus protecting the heart against coronary artery spasm and improving perfusion to the ischaemic myocardium. Nifedipine reduces the frequency of painful attacks and the ischaemic ECG changes irrespective of the relative contribution from coronary artery spasm or atherosclerosis.

In a multi-national, randomised, double-blind, prospective study involving 6321 hypertensive patients with at least one additional risk factor followed over 3 to 4.8 years, Nifedilong 30 and 60 (nifedipine

GITS) were shown to reduce blood pressure to a comparable degree as a standard diuretic combination.

#### Paediatric population

Limited information on comparison of nifedipine with other antihypertensives is available for both acute hypertension and long-term hypertension with different formulations in different dosages. Antihypertensive effects of nifedipine have been demonstrated but dose recommendations, long term safety and effect on cardiovascular outcome remain unestablished. Pediatric dosing forms are lacking.

## **5.2 Pharmacokinetic properties**

### *General characteristics:*

Nifedilong tablets are formulated to provide nifedipine at an approximately constant rate over 24 hours. Nifedipine is released from the tablet at a zero-order rate by a membrane-controlled, osmotic push-pull process. The pharmacokinetic profile of this formulation is characterized by low peak-trough fluctuation. 0-24 hour plasma concentration versus time profiles at steady state are plateau-like, rendering the Nifedilong tablet appropriate for once-a-day administration.

The delivery rate is independent of gastrointestinal pH or motility. Upon swallowing, the biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the faeces as an insoluble shell.

### Absorption

Orally administered nifedipine is almost completely absorbed in the gastrointestinal tract. The systemic availability of orally administered nifedipine immediate release formulations (nifedipine capsules) is 45–56% owing to a first pass effect. At steady-state, the bioavailability of Nifedilong tablets ranges from 68-86% relative to Nifedilong capsules. Administration in the presence of food slightly alters the early rate of absorption but does not influence the extent of drug availability.

### Distribution

Nifedipine is about 95% bound to plasma protein (albumin). The distribution half-life after intravenous administration has been determined to be 5 to 6 minutes.

### Biotransformation

After oral administration, nifedipine is metabolised in the gut wall and in the liver, primarily by oxidative processes. These metabolites show no pharmacodynamic activity. Nifedipine is eliminated in the form of its metabolites, predominantly via the kidneys, with approximately 5-15% being excreted via the bile in the faeces. Non-metabolised nifedipine can be detected only in traces (below 0.1%) in the urine.

### Elimination

The terminal elimination half-life is 1.7 to 3.4 h in conventional formulations (nifedipine capsules). The terminal half-life following Nifedilong administration does not represent a meaningful parameter as a plateau-like plasma concentration is maintained during release from the tablets and absorption. After release and absorption of the last dose the plasma concentration finally declines with an elimination half-life as seen in conventional formulations.

### *Characteristics in patients:*

There are no significant differences in the pharmacokinetics of nifedipine between healthy subjects and subjects with renal impairment. Therefore, dosage adjustment is not needed in these patients.

In patients with hepatic impairment, the elimination half-life is distinctly prolonged and the total clearance is reduced. Owing to the duration of action of the formulation, Nifedilong should not be administered in these patients.

### **5.3 Preclinical safety data**

Preclinical data reveal no special hazards for humans based on conventional studies of single and repeated dose toxicity, genotoxicity and carcinogenic potential.

Following acute oral and intravenous administration of nifedipine in various animal species, the following LD<sub>50</sub> (mg/kg) values were obtained:

Mouse:	Oral: 494 (421-572)*;	i.v.: 4.2 (3.8-4.6)*.
Rat:	Oral: 1022 (950-1087)*;	i.v.: 15.5 (13.7-
Rabbit:	Oral: 250-500;	i.v.: 2-3.
Cat:	Oral: ~ 100;	i.v.: 0.5-8.
Dog:	Oral: > 250;	i.v.: 2-3.

\* 95% confidence interval.

In subacute and subchronic toxicity studies in rats and dogs, nifedipine was tolerated without damage at doses of up to 50 mg/kg (rats) and 100 mg/kg (dogs)

p.o. over periods of thirteen and four weeks, respectively. Following intravenous administration, dogs tolerated up to 0.1 mg/kg nifedipine for six days without damage. Rats tolerated daily intravenous administration of 2.5 mg/kg nifedipine over a period of three weeks without damage.

In chronic toxicity studies in dogs with treatment lasting up to one year, nifedipine was tolerated without damage at doses up to and including 100 mg/kg

p.o. In rats, toxic effects occurred at concentrations above 100 ppm in the feed (approximately 5-7 mg/kg bodyweight).

In a carcinogenicity study in rats (two years), there was no evidence of a carcinogenic effect of nifedipine.

Nifedipine has been shown to produce teratogenic findings in rats, mice and rabbits, including digital anomalies, malformation of the extremities, cleft palates, cleft sternum and malformation of the ribs.

Digital anomalies and malformation of the extremities are possibly a result of compromised uterine blood flow, but have also been observed in animals treated with nifedipine solely after the end of the organogenesis period.

Nifedipine administration was associated with a variety of embryotoxic, placentotoxic and foetotoxic effects, including stunted fetuses (rats, mice, rabbits), small placentas and underdeveloped chorionic villi (monkeys), embryonic and foetal deaths (rats, mice, rabbits) and prolonged pregnancy/decreased neonatal survival (rats; not evaluated in other species). The risk to humans cannot be ruled out if a sufficiently high systemic exposure is achieved, however, all of the doses associated with the teratogenic, embryotoxic or foetotoxic effects in animals were maternally toxic and were several times the recommended maximum dose for humans.

In *in vitro* and *in vivo* tests, nifedipine has not been associated with mutagenic properties.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

#### Tablet Core

Talc

Povidone

Lactose monohydrate

Carbomer 974P

Hypromellose

Silica colloidal anhydrous

Magnesium stearate

Methylene chloride, Water – removed during processing

#### Coating

Talc

Eudragit E

Hypromellose  
Titanium dioxide  
Magnesium stearate  
Macrogol 4000  
Ferric oxide (red)  
Acetone, Denatured alcohol, Isopropyl alcohol – removed during processing

## **6.2. Incompatibilities**

Not applicable.

## **6.3 Shelf life**

The expiry date of the product is indicated on the packaging materials.

## **6.4. Special precautions for storage**

Store below 25°C. Store in the original container in order to protected from light and humidity.

## **6.5 Nature and contents of container**

Blister packs composed of PVC / PVDC/Aluminium white, containing 10, 20, 30, 60 or 100 tablets.

## **6.6. Instructions for use and handling**

No additional information

## **7 MANUFACTURER**

VALPHARMA S.P.A., REPUBLIC OF SAN MARINO  
VIA RANCO 112, SERRAVELLE, REPUBLIC OF SAN MARINO

## **8 LICENSE HOLDER**

CTS CHEMICAL INDUSTRIES LTD  
3 HAKIDMA ST., P.O.B. 385, KIRYAT-MALACHI, ISRAEL

## **9 MARKETING AUTHORISATION NUMBER**

137-89-31415-00  
137-21-31416-00

## **10 DATE OF REVISION OF THE TEXT**

Revised in 03/2025 according to Ministry of Health guidelines.